May. 8 at 5:46 PM
$DERM My prediction for Q1 ER is insurance reimbursement and prescription demand shows improvement, even if not a lot and the stock either bottoms out around
$4.50, or maybe goes to
$5.50 to
$6. And then Q2 or Q3 we get legs again. We already know prescription amount is around 32k for Q1 Which is about 5k more than last quarter. Despite big insurance companies like Aetna and some smaller players starting to cover Emrosi since January, I am predicting 7M revenue for Emrosi and around
$225/prescription. I think market will not freak out about this because it will show a Q to Q improvement of prescriptions going up, and insurance reimbursement also going up.
By Q2 ER we should have insurance covering more of the people requesting prior authorizations for large national plans and also small plans, step therapy patients, more of the 50M lives from the recent expansion, and also captured more revenue for all the off label prescribing happening. There is actually, a good amount of non rosacea off label prescribing happening. So doctors are still learning how much potential Emrosi has, but theyre well aware nothing like it exists for rosacea and they will strongly encourage patients to try and/or keep taking it.
See you guys on the other side.
